Results
infection, bone-defect reduction, SD
INFECTION, WOUND DEHISCENCE, COMPLICATIONS
A total of 25 patients (age range; 17 to 68 years, 11 males and 14 females) participated in this clinical trial, and they were randomly assigned to a control group (n = 9) and two experimental groups (PRF group, n = 8 and CGF group, n = 8). Three patients in the control group and two patients in each experimental group failed to recall at follow-up, and eventually, six patients in each group were analyzed (Fig. 
Demographic data of patientsSD: standard deviation; PRF: platelet-rich fibrin; CGF: concentrated growth factorNo signs of infection or wound dehiscence were observed, and soft-tissue healing was achieved without complications in all patients at recall follow-ups. The mean V
Bone-defect volumes in each group (Mean ± SD, mmV
Comparison of the bone-defect reduction rate (%) between groupsSD: standard deviation; PRF: platelet-rich fibrin; CGF: concentrated growth factor*p-value was calculated using the Kruskal–Wallis test†Post-hoc p-values were calculated using the Mann–Whitney U test with Bonferroni correction**Statistical significance, p < 0.05